Wall Street Zen cut shares of Puma Biotechnology (NASDAQ:PBYI – Free Report) from a strong-buy rating to a buy rating in a research report sent to investors on Saturday morning,Wall Street Zen reports.
PBYI has been the topic of a number of other research reports. TD Cowen boosted their target price on Puma Biotechnology from $5.00 to $6.00 and gave the company a “hold” rating in a report on Friday, August 7th. Weiss Ratings downgraded Puma Biotechnology from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, November 10th. Two equities research analysts have rated the stock with a Hold rating. According to MarketBeat, Puma Biotechnology currently has an average rating of “Hold” and an average target price of $6.00.
Check Out Our Latest Report on Puma Biotechnology
Puma Biotechnology Stock Down 5.5%
NASDAQ PBYI opened at $7.34 on Friday. Puma Biotechnology has a 52-week low of $4.80 and a 52-week high of $11.50. The business’s 50-day moving average price is $9.71 and its 200 day moving average price is $8.03. The firm has a market cap of $379.48 million, a P/E ratio of 15.96 and a beta of 1.40.
Puma Biotechnology (NASDAQ:PBYI – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.06. The firm had revenue of $55.06 million for the quarter, compared to analysts’ expectations of $57.50 million. Puma Biotechnology had a return on equity of 17.50% and a net margin of 10.26%. As a group, analysts anticipate that Puma Biotechnology will post 0.37 earnings per share for the current year.
Insider Transactions at Puma Biotechnology
In related news, Director Alessandra Cesano sold 62,150 shares of Puma Biotechnology stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $9.12, for a total value of $566,808.00. Following the sale, the director directly owned 56,700 shares in the company, valued at $517,104. The trade was a 52.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Troy Wilson sold 5,000 shares of Puma Biotechnology stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $9.10, for a total value of $45,500.00. Following the completion of the sale, the director owned 54,750 shares in the company, valued at approximately $498,225. This trade represents a 8.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 82,150 shares of company stock valued at $733,808. Corporate insiders own 22.20% of the company’s stock.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the business. BlackRock Inc. purchased a new stake in Puma Biotechnology during the second quarter worth about $30,856,000. Globeflex Capital L P acquired a new position in Puma Biotechnology during the second quarter worth about $3,105,000. Wellington Management Group LLP acquired a new position in Puma Biotechnology during the second quarter worth about $1,023,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Puma Biotechnology during the second quarter worth about $5,214,000. Finally, Bank of New York Mellon Corp acquired a new position in Puma Biotechnology during the second quarter worth about $2,926,000. Hedge funds and other institutional investors own 61.29% of the company’s stock.
Puma Biotechnology Company Profile
Puma Biotechnology is a biopharmaceutical company focused on developing and commercializing medicines for cancer treatment. Its work centers on targeted therapies, particularly treatments for breast cancer. The company’s principal product is Nerlynx (neratinib), an oral HER2-targeted medicine. In the United States, it is approved for certain patients with early-stage HER2-positive breast cancer following trastuzumab-based treatment, and for some patients with advanced or metastatic HER2-positive breast cancer in combination with capecitabine.
Recommended Stories
- Five stocks we like better than Puma Biotechnology
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
